The safety profile of GLP-1 RA combined with SGLT2i therapy was comparable to that of SGLT2i monotherapy, with no significant differences observed in the incidence of adverse events, including urinary tract infection, diabetic ketoacidosis, acute pancreatitis, gastroparesis, and intestinal obstruction. The gene discussed is GLP1R; the disease is intestinal obstruction.